» Articles » PMID: 30086574

Plasma Proteolytic Cascade Activation During Neonatal Cardiopulmonary Bypass Surgery

Overview
Journal Thromb Haemost
Publisher Thieme
Date 2018 Aug 8
PMID 30086574
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background:  Neonates undergoing cardiopulmonary bypass (CPB) surgery to correct congenital heart defects often experience excessive bleeding. Exposure of blood to artificial materials during CPB may activate coagulation, complement and inflammatory pathways. In addition, the surgical stress placed on the haemostatic system may result in cross-activation of other plasma proteolytic cascades, which could further complicate physiological responses to the surgical procedure and post-operative recovery. Plasma protease inhibitors undergo distinct conformational changes upon interaction with proteases, and, thereby, can serve as endogenous biosensors to identify activation of the different proteolytic cascades. We tested the hypothesis that changes in the concentration and conformation of protease inhibitors regulating plasma proteolytic cascades during neonatal CPB are associated with post-operative bleeding.

Patients And Methods:  Plasma samples from 44 neonates were obtained at four time points across the surgical procedure. Anti-thrombin, antitrypsin, anti-chymotrypsin, anti-plasmin, C1-inhibitor and tissue factor pathway inhibitor (TFPI) concentrations and conformations were evaluated by enzyme-linked immunosorbent assay, transverse urea gradient gel electrophoresis and sodium dodecyl sulphate-polyacrylamide gel electrophoresis.

Results/conclusion:  The most striking changes were observed following heparin administration and were associated with the appearance of inactive forms of anti-thrombin and an increase in the plasma concentration of TFPI. Changes in anti-thrombin and TFPI remained evident throughout surgery and into the post-operative period but were not different between patients with or without post-operative bleeding. The concentration of antitrypsin decreased across surgery, but there was no significant accumulation of inactive conformations of any inhibitor besides anti-thrombin, indicating that widespread cross-activation of other plasma proteolytic cascades by coagulation proteases did not occur.

Citing Articles

Developmental hemostasis in the neonatal period.

Rey Y Formoso V, Barreto Mota R, Soares H World J Pediatr. 2022; 18(1):7-15.

PMID: 34981411 DOI: 10.1007/s12519-021-00492-3.


Factor V east Texas variant causes bleeding in a three-generation family.

Peterson J, Gupta S, Martinez N, Hardesty B, Maroney S, Mast A J Thromb Haemost. 2021; 20(3):565-573.

PMID: 34847292 PMC: 8885967. DOI: 10.1111/jth.15612.


Major Reservoir for Heparin-Releasable TFPIα (Tissue Factor Pathway Inhibitor α) Is Extracellular Matrix.

Peterson J, Maroney S, Martinez N, Mast A Arterioscler Thromb Vasc Biol. 2021; 41(6):1942-1955.

PMID: 33827254 PMC: 8269748. DOI: 10.1161/ATVBAHA.120.315728.


Platelet Function Changes during Neonatal Cardiopulmonary Bypass Surgery: Mechanistic Basis and Lack of Correlation with Excessive Bleeding.

Zwifelhofer N, Bercovitz R, Cole R, Yan K, Simpson P, Moroi A Thromb Haemost. 2019; 120(1):94-106.

PMID: 31752040 PMC: 7003188. DOI: 10.1055/s-0039-1700517.

References
1.
Damus P, Hicks M, Rosenberg R . Anticoagulant action of heparin. Nature. 1973; 246(5432):355-7. DOI: 10.1038/246355a0. View

2.
Cade J, Hirsh J, Martin M . Placental barrier to coagulation factors: its relevance to the coagulation defect at birth and to haemorrhage in the newborn. Br Med J. 1969; 2(5652):281-3. PMC: 1983203. DOI: 10.1136/bmj.2.5652.281. View

3.
Hezard N, Potron G, Schlegel N, Amory C, Leroux B, Nguyen P . Unexpected persistence of platelet hyporeactivity beyond the neonatal period: a flow cytometric study in neonates, infants and older children. Thromb Haemost. 2003; 90(1):116-23. View

4.
Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen D . Development of the human coagulation system in the full-term infant. Blood. 1987; 70(1):165-72. View

5.
Novotny W, Palmier M, Wun T, Broze Jr G, Miletich J . Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood. 1991; 78(2):394-400. View